TELIK ANNOUNCES PRESENTATION AND WEBCAST AT 5TH ANNUAL ONEMEDFORUM CONFERENCE

Palo Alto, CA – January 4, 2012 – Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate update at the 5th Annual OneMedForum Conference on Wednesday, January 11 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) in San Francisco.  A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.  The archived broadcast of the presentation can be accessed for 30 days following the presentation.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

###

Contact:
Denise San Bartolome
Corporate Communications
Telik, Inc.
Tel: 650 845 7712
Email: denisesb@telik.com

Go to:2012 Press Releases 2011 Press Releases

2010 Press Releases 2009 Press Releases